Analytik Jena Acquires Assets of Molecular Diagnostics Firm
In 2010, Analytik Jena subsidiary AJ Innuscreen began supplying SIRS-Lab with a platform and reagents for automated isolation of nucleic acids for sepsis diagnostics. SIRS-Lab’s primary product, the CE-marked VYOO, is a PCR-based test for the detection of sepsis pathogens. SIRS-Lab was developing SIQNATURE, a gene expression product to show immune response to infection, when it filed for bankruptcy. SIRS-Lab had approximately 30 employees prior to filing for bankruptcy.
Jena, Germany 5/6/13—Analytik Jena announced that it has purchased all the assets of molecular diagnostics company SIRS-Lab. SIRS-Lab’s offerings were for systemic infections, including LOOXSTER technology for the identification and detection of bacterial and fungal DNA in diagnostic samples. The company filed for bankruptcy in December 2012. Analytik Jena has announced it will place a greater emphasis on diagnostics and forming hospital and clinical collaborations. The acquisition marks Analytik Jena’s entry into the sepsis diagnostics market. “In recent years, SIRS-Lab has built up considerable competence in the field of sepsis analytics and has achieved initial successes,” said Analytik Jena CEO Klaus Berka. “The results from a first application study are highly promising. The aim is to identify life-threatening infections quickly and early.” SIRS-Lab was founded in 2000. Analytik Jena will retain 10 SIRS-Lab employees.
